" "

Eliminating hepatitis C

The Health Care Authority (HCA) is partnering with the Department of Health (DOH) to work towards eliminating hepatitis C in Washington State.

Learn more about eliminating hepatitis C in Washington.

Read the Governor's directive

What is hepatitis C?

Hepatitis C virus (HCV) is the most common blood borne disease in the United States. Between 75 and 85 percent of people infected with HCV develop chronic HCV.

Chronic HCV is a lifelong virus that can cause severe scarring (cirrhosis) of the liver, liver cancer, the need for a liver transplant, and even death. The death toll from HCV continues to rise, tied to the opioid epidemic and the rise in drug injection.

About 65,000 Washingtonians live with chronic HCV. Approximately 30,000 are covered by state-purchased health care insurance, including:

  • Washington Apple Health (Medicaid)
  • The Public Employees Benefits Board (PEBB) Program
  • The Department of Corrections (DOC)
  • The Department of Labor & Industries (L&I)

Is there a cure?

Yes. In the past few years, medications have become available that cure HCV.

Numerous national organizations have noted that HCV can be eliminated in the United States in the future. Elimination is a state where HCV is no longer a public health threat, and where those few who become infected quickly learn their status and receive curative treatment, preventing the forward spread of the virus.

HCA, in partnership with other state agencies  — and at the direction of Gov. Jay Inslee — is working to significantly reduce the infected population over the next four years.

Washington State will save money on long-term care by curing those living with HCV, and preventing the spread of the disease. Medicare will save money by curing the younger infected population before they age into Medicare.

Purchasing HCV drugs

HCA is working to secure innovative methods to purchase HCV drugs and to ensure timely access to infected Washingtonians.

Through participation in the State Medicaid Alternative Reimbursement and Purchasing Test for High Cost Drugs (SMART-D) collaborative, HCA released a request for proposals (RFP) for drug manufacturers to bid on January 22, 2019, and on April 25, 2019 announced AbbVie US LLC  as the apparently successful bidder.

AbbVie was chosen because they provided the best overall portfolio to assist Washington with eliminating HCV. They offer a product that will treat about 97 percent of all patients with HCV and they have demonstrated a commitment to partner with HCA to eliminate HCV through its investment in the HepC Free WA initiative.


In order to achieve HCV elimination in Washington State, the Department of Health (DOH) will convene stakeholders to develop an elimination strategy by July 2019. Stakeholders will include:

  • People affected by HCV
  • Local health jurisdictions
  • Tribal Nations
  • Medical providers
  • Others with an interest in HCV elimination


For questions about the RFP
Subject line: HCV Elimination